Co-Diagnostics reports record Q3 revenue of $30.1M, EPS $0.38, guides FY2021 revenue $96-100M

Co-Diagnostics, Inc.

2021-Q3 EPS reported $0.98 revenue$77,484,262

Revenue $30.1M, up 38% YoY; gross profit $26.8M (89.0% margin).
Net income $11.5M ($0.38 diluted EPS) vs $15.7M ($0.53) in Q3 2020.
Cash and marketable securities $83.9M, up $11.5M from June 30, 2021.
FY2021 guidance: revenue $96-100M, diluted EPS $1.07-$1.16, tax rate ~18%.
Unveiled at-home/point-of-care device; JV CoSara cleared dengue/chikungunya tests in India.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.